Re: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Huff
J
J
Waalkes
M
M
Nyska
A
A
Chan
P
P
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000009:adverse effects / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008214:Lymphocytes / Q000187:drug effects*; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D010087:Oxides / Q000009:adverse effects / Q000494:pharmacology*
D000970:Antineoplastic Agents; D001152:Arsenicals; D006131:Growth Inhibitors; D010087:Oxides; D000077237:Arsenic Trioxide